Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial
Top Cited Papers
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 51 (4) , 534-542
- https://doi.org/10.1016/j.jaad.2004.02.021
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseGastroenterology, 2003
- Intramuscular Alefacept Improves Health-Related Quality of Life in Patients with Chronic Plaque PsoriasisDermatology, 2003
- Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probesLupus, 2003
- Anti-TNF-?-induced systemic lupus syndromeClinical Rheumatology, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasisBritish Journal of Dermatology, 1998
- Dermatology in-patient management greatly improves life qualityBritish Journal of Dermatology, 1995
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expressionBritish Journal of Dermatology, 1995